Steakholder Foods Business Summary

Steakholder Foods Ltd. (STKH) operates as a deep-tech pioneer in the alternative protein industry, generating revenue through a multi-pronged B2B model that includes the sale of industrial 3D-printing machinery, proprietary plant-based premix blends (SHMeat and SHFish), and recurring royalty fees from licensing its bioprinting technology. The company’s primary business segments are divided into high-throughput production hardware, such as the MX200 and HD144 printers, and the supply of specialized raw materials required for structured meat and seafood analogs. Following its early 2026 integration of Twine Solutions Ltd., the company has expanded its technological footprint into digital printing and supply chain innovation to enhance production efficiency. Steakholder Foods competes directly with firms like Blue Star Foods (BSFC), Wilk Technologies, and Farmmi (FAMI); however, it distinguishes itself as a specialized infrastructure and technology provider rather than a pure-play consumer food brand, positioning itself as a critical enabler for manufacturers transitioning to sustainable protein production. The company was founded by a team of Israeli entrepreneurs including Arik Kaufman, Yaron Kaiser, Sharon Fima, and Omri Schanin. As of February 2026, the leadership team is headed by Co-founder and CEO Arik Kaufman, a legal and business expert who previously co-founded Bee-io Honey Ltd., and Chairman Yaron Kaiser, a veteran in the high-tech and biotech sectors. Key executive roles include Itamar Atzmony as Chief Engineering Officer, who oversees the development of the company’s complex bioprinting platforms, and Oren Attiya, who serves as the Director of Finance and CFO. The Board of Directors features notable independent members such as Sari Singer, Eli Arad, and David Gerbi, following the early 2026 resignations of Limor Ganot and Snir Wiessman. As a NASDAQ-listed entity, the company maintains a diverse institutional investor base and continues to leverage its founders' pedigree in deep-tech and biotechnology to drive its commercialization phase.